The global gamma knife market size is expected to be valued at US$ 493.2 million in 2026 and projected to reach US$ 727.0 million, growing at a CAGR of 5.7% between 2026 and 2033. It is moderately consolidated, with competition centered on technological innovation, treatment precision, workflow efficiency, and clinical outcomes.

Market participants focus on developing advanced stereotactic radiosurgery systems that offer enhanced imaging integration, improved treatment planning, and greater patient comfort. Strategic investments in research and development, product upgrades, regulatory approvals, and geographic expansion are key approaches to strengthening market presence. Companies are also collaborating with hospitals, cancer centers, and neuroscience institutes to expand access to non-invasive brain disorder treatments.

Drivers - Rising Prevalence of Brain Tumors and Neurological Disorders Fuels Adoption

The escalating global burden of central nervous system (CNS) cancers is a primary catalyst for Gamma Knife system adoption. The American Brain Tumor Association (ABTA) estimates that nearly 700,000 people in the United States are living with a primary brain or spinal cord tumor. Internationally, the International Agency for Research on Cancer (IARC), through the GLOBOCAN 2022 dataset, reported approximately 308,000 new CNS tumor cases globally. Gamma Knife radiosurgery is clinically validated for targeting intracranial lesions with sub-millimeter precision, minimizing collateral tissue damage. Its proven outcomes in acoustic neuroma, meningioma, and metastatic brain tumors have cemented physician preference, translating into sustained demand across neurosurgery departments.

Technological Advancements in Radiosurgery Platforms Expanding Clinical Utility

Innovations in Gamma Knife systems, particularly the Gamma Knife Icon and the advanced Gamma Knife Esprit platforms introduced by Elekta AB, are redefining clinical workflows in stereotactic radiosurgery (SRS). The integration of Cone Beam CT (CBCT) imaging and frameless mask-based immobilization enables hypofractionated treatments previously limited to frame-based systems. As reported by Elekta AB's corporate disclosures, systems equipped with the Leksell Gamma Knife platform have now treated over 1.2 million patients globally. This expanded clinical utility covering not just tumors but trigeminal neuralgia and functional neurosurgery is driving replacement cycles and new installations worldwide.

Restraints - High Capital Cost and Complex Reimbursement Pathways Limit Market Penetration

The significant capital investment required for Gamma Knife systems typically exceeding US$ 4 million per unit installation, presents a substantial barrier to adoption, particularly in low- and middle-income countries (LMICs). Additionally, reimbursement inconsistencies across payer structures create financial uncertainty for hospitals. In the United States, while Medicare and major insurers cover Gamma Knife procedures under stereotactic radiosurgery codes, coverage limits and co-pay structures vary. These financial challenges are exacerbated by high annual maintenance and facility shielding costs, restricting adoption to large academic medical centers in developing markets.

Availability of Alternative Radiosurgery Modalities Constricts Market Share

The Gamma Knife market faces competitive headwinds from alternative stereotactic radiosurgery platforms, including CyberKnife systems from Accuray Incorporated and linear accelerator (LINAC)-based systems by Varian Medical Systems and Brainlab AG. LINAC-based SRS systems offer greater anatomical flexibility beyond the brain, addressing extracranial targets. According to the clinical literature in The Lancet Oncology, LINAC-based radiosurgery demonstrated comparable local tumor control rates for certain brain metastases. This clinical equivalence reduces the unique positioning of Gamma Knife, particularly in facilities that must justify dedicated system investment against multi-purpose LINAC alternatives.

Opportunities - Expansion in Emerging Markets with Increasing Healthcare Infrastructure Investment

Rapid healthcare infrastructure development across Asia Pacific, Latin America, and the Middle East represents a significant growth frontier for Gamma Knife market participants. The World Bank and WHO report that China and India have seen double-digit growth in oncology center establishments over the past decade. Government initiatives such as India's Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) scheme are expanding insurance coverage to over 500 million beneficiaries, increasing access to advanced surgical procedures. Vendors offering modular, cost-optimized Gamma Knife configurations for mid-tier hospitals will be well-positioned to capture accelerating demand from these underserved yet rapidly maturing healthcare markets.

Growing Adoption in Functional Neurosurgery and Trigeminal Neuralgia Treatment

Beyond oncological applications, the growing clinical evidence base for Gamma Knife radiosurgery in trigeminal neuralgia and functional neurosurgery, including treatment of essential tremor and obsessive-compulsive disorder (OCD) is unlocking new application segments. The American Association of Neurological Surgeons (AANS) recognizes Gamma Knife as a primary treatment option for trigeminal neuralgia when surgical access is impractical. The U.S. Food and Drug Administration (FDA) has approved Elekta's Leksell Gamma Knife system for these indications. As functional neurosurgery applications gain wider clinical acceptance and health technology assessment (HTA) bodies increasingly recognize their cost-effectiveness, Gamma Knife vendors stand to benefit from an expanded installed base in neurology departments.

Product Type Insights

The gamma knife icon commands the leading position in the product type category, accounting for 37% of the global market share in 2026. This dominance is attributable to the system's advanced frameless immobilization technology using Cone Beam CT (CBCT) and online adaptive dose delivery, enabling both single-fraction and hypofractionated treatments. Elekta AB's clinical data highlights over 90,000 treatments performed annually on Gamma Knife Icon systems worldwide. The platform's compatibility with existing Leksell Gamma Knife infrastructure simplifies upgrade pathways for existing users. Furthermore, its regulatory approvals across North America, Europe, and Japan have made it the preferred choice for high-volume neurosurgery centers.

Application Insights

The brain tumors application leads the Gamma Knife market, capturing approximately 45% of total revenue in 2026. This dominance reflects the high global incidence of primary and secondary brain malignancies and the clinical preference for non-invasive, precision radiation therapy. The National Cancer Institute (NCI) estimates that brain and other nervous system cancers account for 1.4% of all new cancer cases annually in the United States. Gamma Knife radiosurgery is widely accepted as standard-of-care for brain metastases with fewer than four lesions under 3 cm, as validated by clinical trials published in the New England Journal of Medicine. Its high precision, outpatient delivery, and reduced hospitalization support its sustained leadership in this application.

End-user Insights

Hospitals represent the dominant end-user segment in the Gamma Knife market, accounting for 58% share in 2026. This is underpinned by hospitals' capacity to fulfill the stringent infrastructure requirements of Gamma Knife installations, including radiation shielding, specialized treatment planning suites, and multidisciplinary neurosurgery teams. Large academic medical centers such as Johns Hopkins Hospital and the Cleveland Clinic operate high-volume Gamma Knife programs, contributing substantially to procedure volumes.

The American Hospital Association (AHA) reports that comprehensive cancer centers and tertiary-care hospitals continue to prioritize radiosurgery capital investments. Growing patient referral volumes and insurance authorization support in hospital settings further consolidate this segment's leadership position.

North America Gamma Knife Market Trends and Insights

North America leads the global Gamma Knife market with approximately 38% market share in 2025. The region's dominance reflects well-established reimbursement frameworks, high prevalence of CNS malignancies, advanced neurosurgery infrastructure, and strong adoption of Elekta and other next-generation Gamma Knife platforms across major academic and community medical centers.

U.S. Gamma Knife Market Size

The United States accounts for over 85% of the North American Gamma Knife market, driven by 90,000+ annual brain tumor diagnoses per the NCI, robust Medicare and private insurance coverage for SRS procedures, and dense concentration of high-volume neurosurgery centers operating Leksell Gamma Knife platforms.

Europe Gamma Knife Market Trends and Insights

Europe represents the second-largest regional market, supported by universal healthcare coverage across major economies, high per-capita neurosurgery procedure rates, and a strong base of academic medical centers with established radiosurgery programs. Government investments in oncology infrastructure and favorable European Medicines Agency (EMA) regulatory pathways support steady technology adoption.

Germany Gamma Knife Market Size

Germany accounts for 22% of the European Gamma Knife market, driven by its highly developed hospital infrastructure, statutory health insurance (SHI) coverage of SRS procedures, and leading neurosurgical institutes such as the Heidelberg University Hospital and Charité – Universitätsmedizin Berlin that operate advanced Gamma Knife programs.

U.K. Gamma Knife Market Size

The United Kingdom represents 16% of the European market. The National Health Service (NHS) commissions Gamma Knife treatments at specialist centers including University College London Hospitals (UCLH), with the National Institute for Health and Care Excellence (NICE) endorsing SRS for select CNS indications, supporting sustained procedure volumes.

Asia Pacific Gamma Knife Market Trends and Insights

Asia Pacific is the fast-growing regional market, driven by rapidly expanding oncology infrastructure across China, Japan, India, and Southeast Asia. China leads the regional market with the highest number of new Gamma Knife installations, supported by the central government's Healthy China 2030 initiative, which prioritizes advanced cancer treatment infrastructure. Growing medical tourism in the region and a large, underserved patient population further accelerate demand.

India Gamma Knife Market Size

India represents 12% of the Asia Pacific Gamma Knife market, supported by a rapidly expanding private hospital sector, growing neurosurgery capacity at institutions like Apollo Hospitals and Fortis Healthcare, and rising medical tourism from neighboring countries seeking cost-effective advanced radiosurgery treatment.

The global gamma knife market is moderately consolidated, with Elekta AB maintaining a dominant position as the sole manufacturer of the Leksell Gamma Knife system. Competitive dynamics are shaped by the broader stereotactic radiosurgery ecosystem, with Accuray Incorporated, Varian Medical Systems, and Brainlab AG serving as indirect competitors through LINAC-based SRS platforms. Leading players are focusing on AI-driven treatment planning, system upgrade programs, and emerging market partnerships to expand installed base. Strategic collaborations with academic medical centers for outcomes data generation remain a key R&D differentiator.

Key Developments:

• In July 2025, Elekta’s Leksell Gamma Knife radiosurgery system has received U.S. FDA 510(k) clearance for treating adults with refractory, drug-resistant mesial temporal lobe epilepsy (MTLE). This treatment works by precisely focusing 192 beams of gamma radiation on the seizure focus in the brain, offering a non-invasive alternative to open-skull surgery.
• In May 2025, KIMS Hospital in Hyderabad launched a new Gamma Knife Centre, offering advanced non-invasive radiosurgery technology to treat complex brain disorders with high precision and minimal recovery time.
• In May 2025, AIIMS Delhi, for the first time in India, used Gamma Knife radiosurgery to treat retinoblastoma, a rare eye cancer in young children, applying it to two patients aged 6-7 whose tumors did not respond to standard treatments such as chemotherapy.